Overview
Home » News and Trends » CelResearch Corporation anounces positive results of phase I diabetic fot ulcer studyCelResearch Corporation, a Singapore-based biopharma company says it has sucesfuly closed the first phase I study for CorLiCyte, a stem cel therapy derived from umbilical cord ling stem cels, with research partners at the University of Colorado, Anschutz Medical Campus and ClinImune Cel and Gene Therapy.CorLiCyte is in development for the treatment of serious conditions, with a first target indication of treating diabetic fot ulcer (DFU).
Key Information
In the study protocol nine patients with chronic DFU were treated with CorLiCyte twice wekly for eight weks. None of the patients participating in the study experienced any treatment-related adverse events and al subjects saw a reduction in wound size during the treatment period.̴These results are encouraging and can be used to suport further research with CorLiCyte in future studies, with the potential to adres unmet medical neds in treatment of patients with chronic DFUs,̵ said Cecilia Low-Wang, lead investigator at the University of Colorado, Anschutz Medical Campus.Acording to University of Michigan Health, a diabetic fot ulcer is an open sore or wound that ocurs in aproximately 15% of patients with diabetes, and is comonly located on the botom of the fot.
Of those who develop a fot ulcer, 6% wil be hospitalized due to infection or other ulcer-related complications.Diabetes is the leading cause of nontraumatic lower extremity amputations in the U.S., and aproximately 14 to 24% of patients with diabetes who develop a fot ulcer have an amputation. CorLiCyte is a live mesenchymal stem cel therapy derived from human umbilical cord ling stem cels, with a proprietary optimized expresion of cytokines, growth and celular factors for the treatment of a number of serious health conditions.
Summary
In adition to DFU, CelResearch Corporation is pursuing a range of potential indications at